Synthesis of oxadiazole-2-oxide derivatives as potential drug candidates for schistosomiasis targeting SjTGR
Parasites & Vectors volume 14, Article number: 225 (2021)
Schistosomiasis is a chronic parasitic disease that affects millions of people’s health worldwide. Because of the increasing drug resistance to praziquantel (PZQ), which is the primary drug for schistosomiasis, developing new drugs to treat schistosomiasis is crucial. Oxadiazole-2-oxides have been identified as potential anti-schistosomiasis reagents targeting thioredoxin glutathione reductase (TGR).
In this work, one of the oxadiazole-2-oxides derivatives furoxan was used as the lead compound to exploit a series of novel furoxan derivatives for studying inhibitory activity against both recombinant Schistosoma japonicum TGR containing selenium (rSjTGR-Sec) and soluble worm antigen protein (SWAP) containing wild-type Schistosoma japonicum TGR (wtSjTGR), in order to develop a new leading compound for schistosomiasis. Thirty-nine novel derivatives were prepared to test their activity toward both enzymes. The docking method was used to detect the binding site between the active molecule and SjTGR. The structure–activity relationship (SAR) of these novel furoxan derivatives was preliminarily analyzed.
It was found that several new derivatives, including compounds 6a–6d, 9ab, 9bd and 9be, demonstrated greater activity toward rSjTGR-Sec or SWAP containing wtSjTGR than did furoxan. Interestingly, all intermediates bearing hydroxy (6a–6d) showed excellent inhibitory activity against both enzymes. In particular, compound 6d with trifluoromethyl on a pyridine ring was found to have much higher inhibition toward both rSjTGR-Sec (half-maximal inhibitory concentration, IC50,7.5nM) and SWAP containing wtSjTGR (IC50 55.8nM) than furoxan. Additionally, the docking method identified the possible matching sites between 6d and Schistosoma japonicum TGR (SjTGR), which theoretically lends support to the inhibitory activity of 6d.
The data obtained herein showed that 6d with trifluoromethyl on a pyridine ring could be a valuable leading compound for further study.
Schistosomiasis is one of the most widespread parasitic diseases in the world, and is one of the main tropical endemic diseases in Asia, Africa and South America . It is estimated that approximately 779 million individuals around the world are at risk of schistosomes infection . Schistosomiasis is caused by five species of the trematode flatworm: Schistosoma japonicum (S. japonicum), Schistosoma mansoni (S. mansoni), Schistosoma haematobium, Schistosoma mekongi and Schistosoma intercalatum. When the human body is infected, the worms will persist in the liver, hepatic portal system or the urinary tract system, leading to inflammation and obstructive disease . In China, schistosomiasis is caused mainly by Schistosoma japonicum, and more than 77 thousand people are infected .
The most effective drug for the treatment of schistosomiasis is praziquantel (PZQ) (1), which has been used extensively since the 1980s  in the clinic without any backup drugs. The overuse of praziquantel has caused and accelerated the emergence of drug resistance. While PZQ is very effective against the adult forms of all schistosome species, it is weak for juvenile forms of all schistosomes, which might be the reason that PZQ cannot cure schistosomiasis completely. Although R-PZQ was approved by the Food and Drug Administration (FDA) as an orphan drug in 2018, it is also at risk of resistance, and there is still no alternative drug against the migratory juvenile and subadult worms [6,7,8,9]. Thus, there is an urgent need to look for potential reagents to discover novel alternatives to PZQ for the treatment of schistosomiasis.
It has been reported [1, 10,11,12,13] that instead of separate thioredoxin reductase (TrxR) and glutathione reductase (GR) enzymes of mammalian hosts, a single multifunctional selenocysteine-containing flavoenzyme, thioredoxin glutathione reductase (TGR), plays a critical role in maintaining proper redox balance for parasite survival in both S. mansoni and S. japonicum (Fig. 1). The cellular redox system is important in the physiological function of an organism. Given the biochemical differences between the redox metabolism of schistosomes and host (mammalian), TGR is inferred to be a potential target for new drug design.
In previous studies [1, 2, 10,11,12,13], some oxadiazole-2-oxide analogues have been shown to effectively inhibit SmTGR and SjTGR, even exhibiting prominent worm killing activity in vivo. Importantly, some oxadiazole-2-oxides showed good juvenile and adult S. japonicum killing activity in vitro . Modifications around an oxadiazole-2-oxide skeleton have been demonstrated as a valuable strategy for discovering potential antischistosomal agents. The application of bioisosteres is an effective strategy in drug design. In the design of compounds, previous studies [1, 2, 10,11,12,13] have mainly substituted on the benzene ring and changed the CN moiety, but did not pay attention to modification of the benzene ring and other moieties in the furoxan structure with corresponding bioisosteres. Therefore, in this work, the strategy of applying bioisosteres was exploited to design novel oxadiazole-2-oxide derivatives.
On the other hand, the prokaryotic expression system has been used extensively for protein expression due to its rapid growth rate, capacity for continuous fermentation, and relatively low cost. Due to the lack of the post-translational modifications of this expression system, the bioactivity, function, structure, solubility and so on will be affected to the expressed functional products. Although eukaryotic expression systems can resolve this problem, just like a two-edged sword, some disadvantages such as low yield, demanding culture conditions and higher cost cannot be totally avoided . Thus, the special soluble worm antigen protein (SWAP) containing wtSjTGR extracted from worms might be a better alternative target for studying the bioactivity. It would reflect the actual situation in advance when Schistosoma japonicum is treated with chemical compounds. Therefore, the target compounds herein were also applied to test the inhibition activity on SWAP containing wtSjTGR in addition to rSjTGR-Sec.
In this work, two series of novel furoxan derivatives (7 and 9) (Fig. 2) were obtained through two methods: either by replacing the phenyl moiety of furoxan with its bioisosteres pyridine or substituted pyridine, or by modifying the cyano moiety into an ester or amine group. Because the fluorine atom possesses a strong electron-withdrawing effect and high lipophilicity, appropriate introduction of fluorine atoms into molecules can improve their biofunction . Therefore, several fluorine-containing derivatives were also intentionally synthesized. The target compounds (7 and 9) and their corresponding intermediates (6) (Fig. 2) were tested for their inhibitory activity on TrxR from rSjTGR-Sec and SWAP containing wtSjTGR.. Based on the result obtained, the SAR of these novel furoxan derivatives was preliminarily analyzed.
All chemical reagents involved in synthetic procedures were purchased commercially from J&K Chemicals. The chemical reagents used in activity measurement, including dimethyl sulfoxide (DMSO), ethylene diamine tetraacetic acid (EDTA), dithionitrobenzoic acid (DTNB), and MTT, were purchased from Sigma-Aldrich Inc.
Synthesis of oxadiazole-2-oxide derivatives
The synthesis of compounds 6a–d commenced with the synthesis of α,β-unsaturated esters (4a–d) from substituted nicotinaldehydes (3a–d) by Wittig reaction . Compounds 4a–d were then reduced using diisobutylaluminum hydride (DIBAL-H)  to produce alcohols 5a–d. Subsequent sodium nitrate-mediated cyclization  gave oxadiazole-2-oxides (6a–d) (Scheme 1).
In Scheme 2, compound 7 was readily prepared by esterification of alcohol 6a–d with various acyl chlorides using triethylamine and dimethylaminopyridine (DMAP) as base and catalyst, respectively. The synthesis of target compounds 9 began with the treatment of compounds 6a–d with benzenesulfonyl chloride to generate unstable intermediates 8a–d, which were aminated in situ to afford various target amines 9. As a result, a total of 39 novel oxadiazole-2-oxide derivatives were synthesized and their structures were determined by nuclear magnetic resonance (NMR) and high-resolution mass spectrometry (HRMS). The preparation process and spectrum of the compounds are detailed in Additional file 1.
Normally, two isomers 6 and 6' were obtained (Scheme 1) and one of them was the main product after cyclization. In order to confirm the conformation of main product, its crystal was selected and was measured on a SuperNova diffractometer (dual-source, Cu at zero, EosS2). The crystal was kept at 150 K during data collection. Using Olex2 , the structure was solved with the Superflip structure solution program using charge-flipping and refined with the ShelXL refinement package using least squares minimization.
Preparation of the rSjTGR-Sec and the SWAP containing wtSjTGR
The rSjTGR-Sec was expressed and harvested as described previously [13, 19]. Most of rSjTGR-Sec was expressed in E. coli as a soluble His-tagged fusion protein when bacterial growth occurred at 24 °C. The rSjTGR-Sec was purified by His Mag™ Agarose beads according to manufacturer’s instructions. The concentration of purified rSjTGR-Sec was determined using a Bradford assay kit (Sangon, China), and the protein was identified by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and stored at 4 °C .
The SWAP containing wtSjTGR was prepared from adult schistosomes. Rabbits were infected with cercariae of S. japonicum by exposing their abdominal skin and were sacrificed at 42 days after infection to collect the adult schistosomes by perfusion. The worms were washed three times with phosphate-buffered saline (PBS). After sufficient grinding of the adult schistosomes in PBS, a suitable amount of benzoyl sulfonyl fluoride (PMSF) solution was added to obtain a final concentration of 1 mM. The homogenate was centrifuged at 4 °C, 12,000×g for 20 min [1, 10]. The concentration of supernatant containing wtSjTGR was determined by Bradford assay kit (Sangon, China).
Compound inhibition of rSjTGR-Sec and SWAP containing wtSjTGR
The novel furoxan derivatives in this work were dissolved in DMSO with a storage solution concentration of 64 millimoles per liter. The analysis of TrxR activity of SWAP containing wtSjTGR and rSjTGR-Sec was performed based on methods described previously . Analysis of the inhibitory activity of the compounds against the TrxR activity of SWAP containing wtSjTGR and rSjTGR-Sec described in this paper was also based on a previously described method . The reaction was performed in 0.1 M potassium phosphate buffer (pH 7.0) containing 10 mM EDTA, 100 µM nicotinamide adenine dinucleotide phosphate (NADPH), 0.2 µg supernatant of SWAP containing wtSjTGR or 0.6 µg rSjTGR-Sec, and the studied compounds with different concentrations at 25 °C in a final volume of 200 μL, and was initiated by adding 3 mM DTNB. The increase of the absorbance at 412 nm was monitored, and the IC50 values of the compounds were calculated by GraphPad Prism v6.0c software; The results are reported in Table 1. All assays were done in triplicate.
The crystal structure of SjTGR is a homodimer, and we retained chain B for docking studies . The docking was conducted by AutoDock 4, and the results are displayed in Figs. 4 and 5. The results were further processed and displayed by PyMOL2.3.2. The hydrophobic effects between inhibitors and protein were analyzed by LigPlot+v.2.1, and the result is shown in Fig. 5.
Results and discussion
Synthesis and crystallography
In total, 39 novel oxadiazole-2-oxide derivatives were synthesized following Schemes 1 and 2. The structures of these compounds are detailed in Table 1. During synthesis of the important intermediate 6, two isomers were inevitably formed when the oxadiazole-N-oxide ring was constructed by sodium nitrate-mediated cyclization. Gasco and co-workers reported  that intramolecular hydrogen bond played a crucial role on the formation of the main isomer during cyclization and could stabilize the structure of the isomer a (Scheme 3).
For our case, two isomers, 6 and 6', were obtained (Scheme 1), and one of them was the main product after cyclization. To confirm the position of the N-oxide moiety, and whether the main product was 6 or 6', the crystal of the main product was obtained. It was interesting that the X-ray confirmed that the main product had a similar conformation with isomer a in Scheme 3, and specifically, the main product was 6a (Scheme 1). The crystal structure showed that there were two independent molecules in an asymmetric unit (Fig. 3a). One molecule’s nitrogen atoms were labeled N1, N2 and N3, and the other molecule’s nitrogen atoms were labeled N4, N5 and N6. However, intermolecular hydrogen bonds, instead of intramolecular hydrogen bonds, were found in the crystal of 6a. The molecule’s nitrogen atoms labeled N1, N2 and N3 formed a hydrogen bond helix chain (Fig. 3b), while the nitrogen atoms labeled N4, N5 and N6 formed a hydrogen bond zigzag chain (Fig. 3c). This result also indicated that after the pyridine replaced the benzene, the intramolecular hydrogen bond shown in Scheme 3 might not be necessary for the formation of main isomer 6a–d.
TGR activity assessment
With furoxan as the positive control, oxadiazole-2-oxides (6, 7, 9) were evaluated for their inhibitory activity against both rSjTGR-Sec and SWAP containing wtSjTGR under different concentrations (Table 1). As shown in Table 1, all intermediates bearing hydroxy (6a–6d) showed better inhibitory activity against both enzymes than furoxan. The pyridine ring in the structure of compound 6a had a stronger electron-withdrawing effect on the oxadiazole-2-oxide ring than compound 6b, and 6a (IC50 70nM of SWAP containing wtSjTGR, IC50 36nM of rSjTGR-Sec) had better inhibitory activity on both enzymes than 6b (IC50 0.14µM of SWAP containing wtSjTGR, IC50 0.39µM of rSjTGR-Sec). Compared with 6b, the electron-donating methoxy group at the ortho position of pyridine (like compound 6c) decreased the inhibitory activity (6c, IC50 1.1µM of SWAP containing wtSjTGR, IC50 2.4µM of rSjTGR-Sec). Notably, electron-withdrawing group trifluoromethyl made 6d exhibited excellent inhibitory effect (IC50 7.5nM of SWAP containing wtSjTGR, IC50 55.8nM of rSjTGR-Sec). These data indicated that the electron-withdrawing substituents very possibly provided enhanced potency.
To further investigate the relationship between the structure and bioactivity, modification of hydroxyl group into the ester group and amine, respectively, afforded compounds 7 and 9. It was found that the ester group could not effectively improve the inhibitory effect, although the ethyl ester (7ca), chloracetyl ester (7ae, 7be), benzoyl ester (7af, 7cf) and acryloyl ester (7bj) exhibited inhibitory effects similar to furoxan. Only 7ca (IC50 34.77µM of SWAP containing wtSjTGR) showed inhibitory effects against SWAP containing wtSjTGR, but not as good as furoxan. Among chloracetyl esters, perhaps because the pyridine ring of 7ae had a stronger electron-withdrawing effect, 7ae (IC50 4.23µM of SWAP containing wtSjTGR) showed a slight advantage over 7be (IC50 16.40µM of SWAP containing wtSjTGR, IC50 14.82µM of rSjTGR-Sec). However, 7ae did not show an effective inhibitory effect on rSjTGR-Sec. As for phenyl derivatives, 7af (IC50 8.87µM of SWAP containing wtSjTGR, IC50 3.23µM of rSjTGR-Sec) and 7cf (IC50 12.51µM of SWAP containing wtSjTGR) did not differ significantly in inhibiting SWAP containing wtSjTGR, but 7cf did not show an inhibitory effect on rSjTGR-Sec. Among acrylate compounds, only 7bj showed inhibitory activity against SWAP containing wtSjTGR (IC50 5.80µM).
Some amine derivatives (9aa, 9ab, 9bd, 9be, 9da) showed inhibitory activity, among which 9bd had an inhibitory effect against SWAP containing wtSjTGR at the nanomolar level (IC50 = 42nM). Compared with phenyl amino derivative 9aa, 9ba, 9ca and 9da, the pyridine with strong electron-withdrawing ability improved the activity, such as compounds 9aa (IC50 21.57µM to SWAP containing wtSjTGR) and 9da (IC50 11.62µM to SWAP containing wtSjTGR, IC50 3.73µM to rSjTGR-Sec) showed better inhibition effects than 9ba (IC50 > 50µM) and 9ca (IC50 > 50µM). Similar to phenyl amino derivatives, 4-trifluoromethoxyphenyl amino derivative 9ab (IC50 0.62µM to SWAP containing wtSjTGR, IC50 1.52µM to rSjTGR-Sec) showed better inhibitory effects than 9bb (IC50 > 50µM both to SWAP containing wtSjTGR and rSjTGR-Sec). However, among piperazine substituted derivatives (9ac, 9ad and 9bd), 9bd exhibited good inhibitory activity against SWAP containing wtSjTGR (IC50 0.042µM). Interestingly, compound 9be is an intermediate of a synthetic target molecule, but it displayed much better inhibitory effects (IC50 0.63µM to SWAP containing wtSjTGR, IC50 0.22µM to rSjTGR-Sec) than furoxan. Perhaps the sulfamine or Si-O-N moieties in molecule 9be has some influence on enzyme inhibition ability; this result might provide a new direction for the design of additional compounds.
To rationalize the obtained bioactivity data and to understand how the synthesized inhibitors interact with schistosomal proteins, the selected compounds with high activity 6d, 7af and 9ab were docked to the available crystal structure of SjTGR (thioredoxin glutathione reductase from Schistosoma japonicum, PDB ID:4LA1). The crystal structure of SjTGR is a homodimer, and we retained chain B for docking studies. The results are displayed in Figs. 4 and 5.
Compound 6d formed four hydrogen bonds with Asp433, Ser117 and Thr153, and a π-cation interaction with Arg393 (Fig. 4a), and two strong hydrogen bonds existed between the hydroxyl moiety of 6d and SjTGR. These results could explain the highest activity of 6d. Compound 7af formed two hydrogen bonds with Cys154 and Asp433, and a π-cation interaction with Arg393 (Fig. 4b), while the pyridine ring and oxadiazole ring did not form any type of interactions with the residues of Arg393. Compound 9ab formed one hydrogen bond with Ser276, a π-cation interaction with Arg393 and a π-π stacking interaction with Tyr296. It was observed that the oxadiazole ring participated in the formation of chemical bonds, to constitute more interaction bonds. The distance between the oxadiazole ring and other ring-shaped conjugated structures should be taken into consideration. After superimposing three compounds (6d, 7af and 9ab) together (Fig. 4d), each of them formed one π-cation interaction with Arg393; therefore, it was speculated that Arg393 played an anchor role during the binding process.
On the other hand, a hydrophobic effect was shown by red arcs with spokes radiating toward the atoms involved (Fig. 5). The numbers of the residues that had hydrophobic contacts with the inhibitors were negatively associated with enzyme inhibitory activity. Among three compounds (6d, 7af and 9ab), compound 7af had the most hydrophobic contacting residues and it had the lowest activity, while compound 6d had the least hydrophobic contacting residues and it exhibited the highest activity.
Using furoxan as the leading compound, a series of novel esters and amine derivatives have been synthesized by modifying the cyano moiety into an ester or amine group and replacing phenyl moiety with its bioisosteres pyridine or substituted pyridine. The structure of the key intermediate for target compounds was confirmed by crystallography. The inhibitory activity of all title compounds and key intermediates was evaluated against the TrxR activity of both rSjTGR-Sec and SWAP containing wtSjTGR for the first time. Several new derivatives, 6a–d, 9ab, 9bd and 9be, showed better activity toward rSjTGR-Sec or SWAP containing wtSjTGR than furoxan. The SAR of these novel furoxan derivatives was preliminarily analyzed. A pyridine ring with strong electron-withdrawing ability might be beneficial for enhancing the inhibitory effect. Docking studies showed that hydroxyl moiety can form two strong hydrogen bonds with SjTGR, which is of great help in enhancing the inhibitory activity of the compounds. Compound 6d with trifluoromethyl on the pyridine ring has the highest activity and is a good SjTGR inhibitor and could be a potent antischistosomal agent.
Availability of data and materials
Data supporting the conclusions of this article are included within the article and its additional file.
Thioredoxin glutathione reductase
Schistosoma japonicum TGR
Schistosoma mansoni TGR
Recombinant Schistosoma japonicum TGR containing selenium
Soluble worm antigen
Nicotinamide adenine dinucleotide phosphate
Nuclear magnetic resonance
High-resolution mass spectrometry
Sodium dodecyl sulfate polyacrylamide gel electrophoresis
Ethylene diamine tetraacetic acid
Benzoyl sulfonyl fluoride
Song L, Li J, Xie S, Qian C, Wang J, Zhang W, et al. Thioredoxin glutathione reductase as a novel drug target evidence from Schistosoma japonicum. PLoS ONE. 2012;7:e31456.
Song LJ, Luo H, Fan WH, Wang GP, Yin XR, Shen S, et al. Oxadiazole-2-oxides may have other functional targets, in addition to SjTGR, through which they cause mortality in Schistosoma japonicum. Parasites Vectors. 2016;9:1–12.
Gryseels B, Polman K, Clerinx J, Kestens L. Human schistosomiasis. Lancet. 2006;368:1106–18.
Zhang LJ, Xu ZM, Qian YJ, Dang H, Lv S, Xu J, et al. Endemic status of schistosomiasis in People’s Republic of China in 2015. Chin J Schisto Control. 2016;28:611–7.
Thetiot-Laurent SAL, Boissier J, Robert A, Meunier B. Schistosomiasis chemotherapy. Angew Chem Int Ed. 2013;52:7936–56.
Cioli D, Pica-Mattoccia L, Basso A, Guidi A. Schistosomiasis control: praziquantel forever? Mol Biochem Parasitol. 2014;195:23–9.
Guglielmo S, Cortese D, Vottero F, Rolando B, Kommer VP, Williams DL, et al. New praziquantel derivatives containing NO-donor furoxans and related furazans as active agents against Schistosoma mansoni. Eur J Med Chem. 2014;84:135–45.
Sadhu PS, Kumar SN, Chandrasekharam M, Pica-Mattoccia L, Cioli D, Rao VJ. Synthesis of new praziquantel analogues: potential candidates for the treatment of schistosomiasis. Bioorg Med Chem Lett. 2012;22:1103–6.
Zheng Y, Dong L, Hu C, Zhao B, Yang C, Xia C, et al. Development of chiral praziquantel analogues as potential drug candidates with activity to juvenile Schistosoma japonicum. Bioorg Med Chem Lett. 2014;24:4223–6.
Sayed AA, Simeonov A, Thomas CJ, Inglese J, Austin CP, Williams DL. Identification of oxadiazoles as new drug leads for the control of schistosomiasis. Nat Med. 2008;14:407.
Rai G, Sayed AA, Lea WA, Luecke HF, Chakrapani H, Prast-Nielsen S, et al. Structure mechanism insights and the role of nitric oxide donation guide the development of oxadiazole-2-oxides as therapeutic agents against schistosomiasis. J Med Chem. 2009;52:6474–83.
Bonilla M, Denicola A, Novoselov SV, Turanov AA, Protasio A, Izmendi D, et al. Platyhelminth mitochondrial and cytosolic redox homeostasis is controlled by a single thioredoxin glutathione reductase and dependent on selenium and glutathione. J Biol Chem. 2008;283:17898–907.
Kuntz AN, Davioud-Charvet E, Sayed AA, Califf LL, Dessolin J, Arnér ES, et al. Thioredoxin glutathione reductase from Schistosoma mansoni: an essential parasite enzyme and a key drug target. PLos Med. 2007;4:e206.
Yin J, Li G, Ren X, Herrler G. Select what you need: a comparative evaluation of the advantages and limitations of frequently used expression systems for foreign genes. J Biotechnol. 2007;127:335–47.
Gillis EP, Eastman KJ, Hill MD, Donnelly DJ, Meanwell NA. Applications of fluorine in medicinal chemistry. J Med Chem. 2015;58:8315–59.
Sano S, Yokoyama K, Fukushima M, Yagi T, Nagao Y. New reaction mode of the Horner–Wadsworth–Emmonsreaction using Sn(OSO2CF3)2 and N-ethylpiperidine. Chem Commun. 1997;28:559–60.
Rai G, Thomas CJ, Leister W, Maloney DJ. Synthesis of oxadiazole-2-oxide analogues as potential antischistosomal agents. Tetrahedron Lett. 2009;50:1710–3.
Dolomanov OV, Bourhis LJ, Gildea RJ, Howard JAK, Puschmann H. OLEX2: a complete structure solution, refinement and analysis program. J Appl Crystallogr. 2009;42:339–41.
Rengby O, Johansson L, Carlson LA, Serini E, Vlamis-Gardikas A, Karsnas P, et al. Assessment of production conditions for efficient use of Escherichia coli in high-yield heterologous recombinant selenoprotein synthesis. Appl Environ Microbiol. 2004;70:5159–67.
Alger HM, Williams DL. The disulfide redox system of Schistosoma mansoni and the importance of a multifunctional enzyme, thioredoxin glutathione reductase. Mol Biochem Parasitol. 2002;121:129–39.
Han Y, Zhang M, Hong Y, Zhu Z, Li D, Li X, et al. Characterization of thioredoxin glutathione reductase in Schiotosoma japonicum. Parasitol Int. 2012;61:475–80.
Peng Y, Wu Q, Huang F, Chen J, Li X, Zhou X, et al. Crystal structure of SjTGR complex with FAD. RCSB PDB. http://www.rcsb.org/structure/4LA1. Accessed 15 Oct 2019.
Gasco AM, Fruttero R, Sorba G, Gasco A. Unsymmetrically substituted furoxans, XIII. Phenylfuroxancarbaldehydes and related compounds. Eur J Org Chem. 1991;11:1211–3.
This work was supported by the National Natural Science Foundation of China (No. 81773560 and No. 31402192).
Ethics approval and consent to participate
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Li, G., Guo, Q., Feng, C. et al. Synthesis of oxadiazole-2-oxide derivatives as potential drug candidates for schistosomiasis targeting SjTGR. Parasites Vectors 14, 225 (2021). https://doi.org/10.1186/s13071-021-04634-4